Online analysis based on ERS 2022 mentions
in the period 28 August – 10 September 2022
04 – 06 SEPT
2022
This year’s European Respiratory Society’s Congress (ERS) was held in Barcelona, Spain. The event welcomed thousands of delegates to unravel the newest advances in respiratory medicine and science. The scientific programme featured cutting-edge scientific sessions, practical workshops, interactive educational content and networking opportunities for visitors and companies that both exhibited and attended the congress.
Volume over time is tracked back to one month before the event when most exhibitors started announcing their participation.
Relative shares (in percents) are calculated out of all categorised posts within the respective social media.
In comparison to last year’s ERS Brand Buzz Report, the top 5 most discussed topics have changed slightly. With COVID-19 now taking the third place, followed by Training & Education and Innovations in Sleep Care & Therapy, the first and second places are taken by two brand new topics—Sleep-Related Disorders and Treatment of Sleep Disorders (including medication).
In Twitter only, COVID-19 ranked higher than Training Education & Innovations.
* Relative shares are calculated out of all categorised posts within the respective social media.
The top brands that have generated the most engagement with their social media activity – likes, comments, reshares, etc
What did the highest-ranking companies in Brand Buzz analysis talk about?
Chiesi’s focus during this year’s ERS Congress narrowed to three different areas of study, but what stood out was the company’s dedication to co-creating smart and human solutions. The company supported the launch of the new International Respiratory Coalition ‘Lung Facts’ – a web-based tool with key economical and epidemiological data for respiratory conditions across Europe.
GSK’s top voices—Dr. Susie Barnes, Dr. Marco Avila and Dr. Piyali Mukherjee presented 31 abstracts from the brand’s portfolio of biologics, vaccines and inhaled medicines. Their research aims to redefine what is possible for patients.
AstraZeneca took a closer look at chronic respiratory and immune-mediated diseases. The company strives to transform care, with bold ambition to go beyond controlling symptoms, to slow down or reverse the course of disease.
Join our newsletter
By subscribing you agree with our Privacy Policy
Privacy Policy
Terms of Service
Cookies Settings
Copyright NPS® is a registered trademark, and Net Promoter Score℠ and Net Promoter System℠ are service marks, of Bain & Company, Inc., Satmetrix Systems, Inc. and Fred Reichheld.
Web development by MySuper.Site
